Table 1.
Study | Study design | Country | Study period | Patients characteristics | Clinical course | Outcomes |
---|---|---|---|---|---|---|
Schlage et al. [15] | Systematic review (45 studies) | Multinational: Europe, North America, South America, Africa, Asia | Apr 2020–Oct 2020 (online publication) | 1,003 Pediatric cancer patients aged <18 years | Asymptomatic (23.9%), mild or moderate (41.7 %), severe (11.1%) | Died (2.5%) |
Wang et al. [16] | Systematic review (33 studies) | Multinational: Italy, US, Spain, Switzland, Austria, Poland, France, Georgia, US, Mexico, Peru, Brazil, India, China, Egypt | Oct/20/2020 (study search) | 226 Pediatric cancer patients aged <18 years | Asymptomatic (30.1%), mild (18.1%), moderate (4.3%), severe (9.6%) | Hospitalized (47%), ICU admission (10.3 %), given oxygen (32.3%), died (4.9 %) |
Haeusler et al. [18] | Observational cohort study | Multinational: Austria, Italy, Germany, UK, Switzerland, Brazil, Canada, Russia, Israel, Australia | Beginning of the pandemic – Feb/28/2021 | 131 Pediatric patients with cancer or HSCT aged <19 years: leuke- mia (46%), lymphoma (14%), solid tumor (37%), HSCT for primary immunodeficiency (4%) | Asymptomatic (32%), mild (47%), moderate (8%), severe (4%), critical (9%) | ICU admission (11%), died (3%) |
Mukkada et al. [19] | Cohort study | Multinational (131 institu- tions in 45 countries) | Apr/15/2020– Feb/1/2021 | 1,301 Pediatric patients with can- cer or HSCT aged <19 years: leukemia or lymphoma (49.1%), other hematological malignancies (17.7 %), solid tumor (24.2%), CNS tumor (8.4%), post-HSCT for nonmalignancy (0.5%) | Asymptomatic (35%), mild or moderate (45 %), severe or critical (19.9%) | Hospitalized (67.4%), ICU admission (17.5 %), died (3.8%) |
Yun et al. [22] | Retrospective study | South Korea | Nov/9/2020– Nov/18/2020 | 181 Pediatric and young adult cancer patients who exposed to the index case | 3 Infected patients were asymptomatic or mildly symptomatic | |
Arous et al. [25] | Retrospective study | Algeria | - | - | - | Died (28%) |
CNS, central nervous system; HSCT, hematopoietic stem cell transplantation; ICU, intensive care unit.